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Background: Hepatitis E virus (HEV) is the most recently discovered of the hepatotropic viruses, and is considered
an emerging pathogen in developed countries with the possibility of fulminant hepatitis in immunocompromised
patients. Especially in the latter elevated transaminases should be taken as a clue to consider HEV infection, as it
can be treated by discontinuation of immunosuppression and/or ribavirin therapy. To our best knowledge, this is a
unique case of autochthonous HEV infection with coincident reactivation of Epstein-Barr virus (EBV) infection in an
immunosuppressed patient with rheumatoid arthritis (RA).
Case presentation: A 68-year-old Swiss woman with RA developed hepatitis initially diagnosed as methotrexate-
induced liver injury, but later diagnosed as autochthonous HEV infection accompanied by reactivation of her latent
EBV infection. She showed confounding serological results pointing to three hepatotropic viruses (HEV, Hepatitis B
virus (HBV) and EBV) that could be resolved by detection of HEV and EBV viraemia. The patient recovered by
temporary discontinuation of immunosuppressive therapy.
Conclusions: In immunosuppressed patients with RA and signs of liver injury, HEV infection should be considered,
as infection can be treated by discontinuation of immunosuppression.
Although anti-HEV-IgM antibody assays can be used as first line virological tools, nucleic acid amplification tests
(NAAT) for detection of HEV RNA are recommended – as in our case - if confounding serological results from other
hepatotropic viruses are obtained. After discontinuation of immunosuppressive therapy, our patient recovered from
both HEV infection and reactivation of latent EBV infection without sequelae.
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Hepatitis E virus (HEV) is a non-enveloped single-stranded
RNA virus approximately 27–34 nm in diameter belonging
to the genus Hepevirus in the Hepeviridae family.
It is the most recently discovered of the hepatotropic
viruses, with four different HEV genotypes (GT) that
represents a single serotype able to infect humans [1].
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Americas, Europe and Asia, and for GT4 in Asia, where
they are also found in pigs and wild animals [2]. It has
recently become obvious that HEV is endemic in indus-
trialized countries, and that more infections are autoch-
thonous (locally acquired) than travel-associated [3].
HEV infection has to be considered as a zoonosis and
viral transmission from animals (pigs, wild animals) oc-
curs through food or direct contact [1]. In high-income
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both asymptomatic infections in healthy individuals as
well as fulminant hepatitis in mostly immunocomprom-
ised patients [4]. Although it is now considered to be an
emerging disease, HEV infection is yet not a notifiable
disease in Switzerland [5].
We present a unique case of autochthonous HEV in-
fection in a Swiss woman with coincident reactivation of
Epstein-Barr virus (EBV) infection under immunosup-
pression of her RA.
Case presentation
On April 22nd 2015 a 68-year-old Swiss woman com-
plained about nausea, headache and fever. She had
slightly elevated transaminases and elevated C-reactive
protein. The general practitioner interpreted the abnor-
mal liver function tests as complication of MTX therapy
she had received for treatment of RA since 2002. As
transaminases increased over the following eight days to
values above upper limit in point-of-care testing, the pa-
tient was admitted with preliminary diagnosis of MTX-
induced liver injury [6]. On admission the patient com-
plained of nausea, pain below right rib cage and in lower
extremities and buttocks. She was afebrile, showed no
jaundice and further physical examination was unre-
markable. Abdominal ultrasound showed slight liver
steatosis. Liver magnetic resonance imaging revealed
no further abnormalities. The low-dose MTX therapy
(10 mg/week) for erosive RA (positive for anti-cyclic
citrullinated peptide-antibody) and the weekly predni-
solon dosis (5mg) that she had received for treatment
of chronic obstructive lung disease were stopped. The
therapy with bronchodilators (ipratropium bromide,
budenoside, albuterol) was continued.
Liver transaminases, alkaline phosphatase, gamma-
glutamyl transferase, and acute phase proteins (C-reactive
protein, ferritin, haptoglobin) were elevated (Table 1). Leu-
kocytes and platelets were slightly above normal reference
limit. Bilirubin, prothrombin time, and activated partial
thromboplastin time laid within normal ranges. Serology
for hepatotropic viruses and parasites (Hepatitis A virus,
Hepatitis C virus, Cytomegalo-virus (CMV), Echinococcus
alveolaris, Echinococcus granulosus, Toxoplasma gondii)
and anti-mitochondrial-antibody as well as markers for
autoimmune hepatitis (anti-liver kidney microsome type
1-, anti-smooth muscle-, anti-soluble liver antigen- anti-
body) were negative.
To note, tests for specific IgM-antibody against EBV
viral capsid antigen (VCA), Hepatitis B-Virus (HBV)-
core-antigen (Architect®, Abbott, Wiesbaden, Germany),
and HEV (Diapro, Milan, Italy) were positive, indicating
a recent infection with three different viruses. Subse-
quent viral load testing revealed low copy numbers of
EBV DNA (928 copies/ml corresponding to 566 IU/mlcalibrated to World Health Organisation EBV standard;
TaqMan real-time PCR assay according to Berger et al.
[7] with modified primers) and HEV RNA (8959 copies/
ml; Real-time reverse transcriptase (RT)–PCR assay ac-
cording to Jothikumar et al. [8] with minor primer modi-
fications to account for HEV genotypic diversity). No
HBV DNA could be detected in plasma (COBAS
AmpliPrep-COBAS TaqMan 48 HBV Test, Version 2.0,
Roche, Switzerland). Additional HEV IgG- and IgM-
specific ELISA tests (Beijing Wantai Biological Pharmacy
Enterprise), retrospectively done on a serum sample
from day 8 of illness confirmed positive results.
One month follow-up showed clearing of both Hepatitis
E- and Epstein-Barr viral load and seroreversion of anti-
HB core-IgM and anti-HB core-Ig antibody, with signifi-
cant increase of HEV IgG index. Results of blood tests are
shown in Table 1.
The patient fully recovered after 40 days and suffered
no relapse after reinitiation of MTX and prednisolon
therapy, in the following five weeks.
Discussion
Although HEV infection is often asymptomatic and only
occasionally induces a self-limited acute hepatitis with
low mortality, it can, however, be more severe in
immune-suppressed individuals [4]. Acute HEV infec-
tion can be diagnosed either directly by detecting the
viral genome in biologic specimens (e.g. stools, liver bi-
opsy) or indirectly by detecting specific IgM and IgG
antibodies against the virus [2]. In plasma, HEV RNA
may be detected at low levels with onset of illness, per-
sisting for up to 4 weeks. In immunosuppressed patients,
HEV diagnosis by detection of HEV RNA is recom-
mended, as testing for antibodies may give false negative
results due to immunosuppression [2]. The detection of
HEV specific-IgG and -IgM can be delayed in immuno-
suppressed patients e.g. after liver transplantation, with a
diagnostic window of several weeks between the first de-
tection of HEV RNA and the detection of HEV-specific
antibodies [9]. In blood samples of 35 immunosup-
pressed solid-organ transplant patients and five haem-
atological patients, drawn at the time of first elevation of
the ALT activity and positive for HEV RNA, Abravanel F
et al. [10] reported a sensitivity of 85 % (95 % CI: 70.2-
94.3) for detection of HEV specific-IgM antibodies
(ELISA Kit, Beijing Wantai Biological Pharmacy Enter-
prise). The authors concluded, that well validated anti-
HEV-IgM assays can be used as first line virological tool
in immunosuppressed patients, but molecular detection
of HEV RNA is essential, if anti-HEV IgM tests turn out
negative.
Furthermore, serological testing is hindered either by
the potential inability to detect anti-HEV IgM or by false
positive HEV-IgM results that have been reported to
Table 1 Evolution of laboratory parameters and discontinuation of therapy
Parameter (Reference or limit of detection) Day after onset of illness
8 9 12 21 40 75
AST (<40 U/l) 1920 1787 578 53 31 26
ALT(<55 U/l) 1743 1650 1021 122 27 25
yGT(<35 U/l) 265 226 221 102 35 20
ALP (42–98 U/l) 352 296 302 150 70 58
Bilirubin (<20 umol/l) 15 15 13 16
CRP(<5 mg/l) 41 35 14 37 12 4
CMV IgG (neg) Neg
CMV IgM (neg) Neg
Hepatitis A IgM (neg) Neg
HBs Antigen (neg) Neg
HBc Ig (neg) Pos Neg
HBc IgM (neg) Pos Neg
HBe Ig (neg) Neg Neg
HBe Antigen (neg) Neg
HBs Ig (neg) Neg
HBV DNA (<9 IU/ml) <9
Hepatitis C Ig (neg) Neg
EBV VCA IgG (neg) Pos
EBV NA1 IgG (neg) Pos
EBV VCA IgM (neg) Pos Pos
EBV DNA (<122 IU/ml) 566 <122 <122
Heterophile IM (neg) Neg
HEV IgG (neg); Diapro Pos
HEV IgM (neg); Diapro Pos
HEV IgG (<1.0 index); Wantai 5.3 19.4 19.5
HEV IgM (<1.0 index); Wantai 10.4 10.6 10.6
HEV RNA (<1000 cc/ml) 8959 <1000 <1000
Stop (\) and reinitiation (/) of
- Prednisolon therapy 8 \ / 48
- Methotrexate therapy 8 \ / 63
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EBV and CMV. In the latter case, false positive HEV-
IgM antibodies may appear, e.g., as a consequence of
polyclonal B-cell stimulation by EBV infection or –
rarely - crossreactive EBV-specific IgM antibodies. Since
liver involvement is not rare in both viruses, acute hepa-
titis may be incorrectly diagnosed as being due to HEV
infection or (vice versa) to EBV or CMV infection, re-
spectively, if the diagnosis is not confirmed by molecular
tests [11, 12].
Although the classical presentation of acute HEV infec-
tion is with general malaise, fever, jaundice accompanied
by pale stools, darkened urine and gastrointestinal symp-
toms, this phenotype is rarely seen with HEV GT3 and 4in high income countries [2]. Our patient had mild gastro-
intestinal symptoms, lacking jaundice. In such atypical
cases, liver enzyme elevations especially elevated aspartate
transaminase (AST) and alanine transaminase (ALT) are
the clue for the correct diagnosis, but may be incorrectly
ascribed to other acute hepatic diseases such as drug-
induced liver injury [2]. In our patient, elevated liver en-
zymes were initially interpreted as complication of MTX
therapy, despite folic acid supplementation that lowers fre-
quency of liver function abnormalities. Although low-dose
MTX therapy is considered immunosuppressive, it does
not increase infection risk in patients with RA, that per se
have a higher rate of infection when compared with a
healthy control population [13]. A french retrospective
Schultze et al. BMC Infectious Diseases  (2015) 15:474 Page 4 of 5multicenter study [14] demonstrated that HEV infection
should be suspected in patients with RA and elevated
liver enzyme levels. Among RA patients in this study,
HEV infection had been treated by discontinuation of
immunosuppressive therapy to allow restoration of T
cell responses against the virus and by ribavirin therapy
when liver enzyme levels were particularly elevated and/
or when the activity of the inflammatory arthritis re-
quired immunosuppressive drugs. Nearly half of all pa-
tients including other inflammatory rheumatic diseases
reported in this study by Bauer et al. were totally
asymptomatic, emphasizing the need to specifically look
for HEV in the checkup of elevated liver enzymes, re-
gardless of the symptoms [14].
HEV GT3 infection in immunocompromised patients
may become chronic, defined as HEV RNA detectable
for more than 6 months, leading to chronic hepatic in-
flammation and rapidly progressive cirrhosis, as in pa-
tients chronically infected with hepatitis C virus [2].
In our patient, discontinuation of MTX and prednisol-
one therapy during one month, i.e., time from hospital
admission (day 8) and the day of the first negative PCR
result for HEV RNA (day 40), was sufficient to clear
both HEV RNA and EBV DNA. This is in the range of
the french study [14], in which 9 of 12 patients with RA
(7 females; median 61 yr , range 44–72 yr ) received
MTX, partially in combination with a biologic (e.g.Ritux-
imab), corticosteroid and/or disease-modifying drug
(Leflunomide). After discontinuation of immunosup-
pressive therapy, the median time of HEV RNA positiv-
ity in 10 of these patients was 7 weeks (range 4–10.5
weeks). One 68-year-old man on MTX and Rituximab
received ribavirin for 3 months and the HEV load disap-
peared within 8 weeks. In contrast to our patient, no re-
activation of latent EBV infection was noted. In
accordance with the study patients, the course of acute
HEV in our patient was found to be cytolytic rather than
cholestatic, with a duration of liver cytolysis of <40 days,
compared to <3 months in study patients. Additionally,
our patient experienced no flare of its rheumatic disease
after discontinuation of immunosuppression, whereas it
occurred in half of the study patients at a median of 4
weeks (range 1 day −10 weeks).
EBV persists as a latent infection with episomal DNA
in a very small number of memory B cells, and it is diffi-
cult to detect EBV in the plasma of healthy individuals
[15, 16], whereas in patients with RA there is a 10-fold
systemic EBV overload in peripheral blood mononuclear
cells (PBMCs) due to an impaired immune response to
EBV [17]. MTX therapy of patients with RA may reacti-
vate EBV production [15] by differentiation of memory
B cells into plasma cells that undergo lytic infection and
produce virus [16]. In our patient, concomitantly posi-
tive EBV VCA-IgG, EBV VCA-IgM, and EBNA-1 IgGantibodies were measured. Although this reflects a past
EBV infection in most cases, it may also correspond to
an EBV reactivation episode, a state of polyclonal stimu-
lation by a heterologous infectious agent or to a rela-
tively recent EBV-related primary infection [18]. In our
patient, the low viral load of EBV and a negative test for
heterophile antibodies (Clearview IM; Inverness Medical,
UK) pointed against primary EBV infection and rather
indicated a reactivation of latent EBV [19]. The negative
HBs antigen, anti-HBs-Ig, and anti-HBe-IgG were a hint
to falsely positive anti-HB core-IgM and anti-HB core-Ig
antibody, confirmed by seroreversion one month later.
Taken together, microbiological tests indicated a recent
HEV infection with coincident reactivation of the pa-
tient’s latent EBV infection.
One month after discontinuation of MTX and predni-
solon therapy, neither HEV RNA nor EBV DNA was de-
tectable in the patient’s plasma. Thus, reactivation of the
patient’s EBV-infection might have been triggered by the
HEV infection.
Most HEV transmissions occur by the fecal-oral (GT1
and GT2) and food-borne routes (GT3 and GT4). HEV
has been documented in pig products in the human food
chain across Europe, and shellfish, such as bivalve mol-
lusks, have been shown to act as reservoirs [2] Other
transmission routes, including human to human transfer
[20], vertical transmissions and infection through blood
transfusion have also been described [3]. Environmental
presence of HEV has been demonstrated in sewage sam-
ples of developed countries, where sporadic, locally ac-
quired infections of HEV genotypes 3 and 4 have been
reported during the past decade. These autochthonous
zoonotic infections have been linked to ingestion of raw
or undercooked meat especially from pigs, wild boar,
and deer [2]. In several western European countries in-
cluding Switzerland, seroepidemiological studies suggest
that domestic pigs and wild boars are the main reser-
voirs for human HEV. A significantly lower seropreva-
lence in domestics pigs in Switzerland was observed in
2011 than in 2006, possibly due to the ban in 2008 on
using sewage sludge from water treatment plants as
fertilizer in agriculture [21].
As our patient had not left Switzerland for many years,
she must have acquired an autochthonous infection,
possibly due to consumption of pork spare ribs four
weeks prior to onset of symptoms. Genotyping of the
HEV was not feasible, due to the low viral load that
hampered amplification of cDNA to detectable levels.
Conclusions
In immunosuppressed patients with RA and signs of
liver injury, HEV infection should be considered, as in-
fection can be treated by discontinuation of immunosup-
pression. Although anti-HEV-IgM antibody assays can
Schultze et al. BMC Infectious Diseases  (2015) 15:474 Page 5 of 5be used as first line virological tools, NAAT for detection
of HEV RNA are recommended – as in our case - if
confounding serological results from other hepatotropic
viruses are obtained. After discontinuation of immuno-
suppressive therapy, our patient recovered from both
HEV infection and reactivation of latent EBV infection
without sequelae.
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